Introduction {#Sec1}
============

Progress in the molecular biology of solid tumors has established the important role of tumor angiogenesis and the multiple signaling pathways underlying this process in tumor development \[[@CR1]\]. Moreover, antiangiogenic therapy that targets signaling by the vascular endothelial growth factor (VEGF) pathway represents a key advance in clinical oncology \[[@CR2], [@CR3]\]. Sunitinib (SUTENT®) is an oral multitargeted tyrosine kinase inhibitor of VEGF receptors (VEGFR1 to VEGFR3), platelet-derived growth factor receptors (PDGFRα and PDGFRβ), and other receptor tyrosine kinases \[[@CR4]--[@CR6]\]. It has shown single-agent activity and acceptable tolerability in phase I/II studies of patients with a variety of advanced refractory solid tumors \[[@CR4]\]. The clinical benefits observed with sunitinib have resulted in multinational approval for its use in the treatment of patients with advanced renal cell carcinoma or imatinib-resistant or -intolerant gastrointestinal stromal tumors \[[@CR7], [@CR8]\].

As targeted agents such as sunitinib enter into clinical practice, there is interest in assessment of the efficacy and safety of these agents administered in combination with chemotherapy in cancer patients, including those with treatment-refractory tumors. Preclinical studies indicate that the combination of sunitinib with chemotherapeutic agents results in increased antitumor activity \[[@CR9]\]. One chemotherapeutic agent tested, pemetrexed, is an antimetabolite that suppresses cell replication by inhibiting multiple enzymes in the folate pathway and which shows clinical activity against a broad range of solid tumors, including non-small cell lung cancer (NSCLC) and mesothelioma \[[@CR10]--[@CR12]\]. The adverse effects of sunitinib are largely nonoverlapping with those of pemetrexed, making the latter an appropriate agent, in terms of safety, for combination with sunitinib. We have now performed a feasibility study to assess the safety and tolerability of two dosing schedules of sunitinib (continuous daily dosing \[CDD\] schedule and 2 weeks on treatment followed by 1 week off treatment \[Schedule 2/1\]) in combination with fixed-dose (500 mg/m^2^) pemetrexed.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

Patients with histologically proven advanced solid tumors and who were 20 years of age or older were enrolled in the study. Other key inclusion criteria included: prior treatment with one or more chemotherapy regimens; an Eastern Cooperative Oncology Group performance status of ≤1; resolution of acute toxicities resulting from prior therapy; adequate organ function; and a life expectancy of ≥3 months. Key exclusion criteria included: prior treatment with pemetrexed or sunitinib or irradiation of ≥ 25% of bone marrow; hemoptysis (≥5 mL per episode or ≥10 mL/day) occurring ≤4 weeks before the onset of study treatment; chemotherapy, surgery, or radiation therapy instituted \<4 weeks before the start of the study (with the exception of palliative radiotherapy for nontarget lesions); symptomatic or uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease; a history of cardiac disease, cerebrovascular events, or pulmonary embolism within the 12 months prior to the onset of study treatment; ongoing cardiac dysrhythmias of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade ≥ 2, atrial fibrillation (any grade), or a prolonged QTc interval; hemorrhage of CTCAE grade 3 within the 4 weeks before the start of the study treatment; or hypertension that could not be controlled with standard antihypertensive agents.

Study design and treatment {#Sec4}
--------------------------

The study was a randomized, open-label study (NCT00732992) of sunitinib in combination with pemetrexed in patients with advanced solid tumors. The primary objective was assessment of overall safety, including dose-limiting toxicities (DLTs), for two treatment regimens of sunitinib plus pemetrexed. Secondary endpoints included plasma pharmacokinetic evaluations and preliminary antitumor activity.

Sunitinib was administered orally, once daily, according to either the CDD schedule or Schedule 2/1. Pemetrexed (500 mg/m^2^) was administered as a 10-min infusion on day 1 of a 21-day cycle. Patients were instructed to take 500 μg of folate daily, beginning 1 week before day 1 of cycle 1 until study discontinuation. Vitamin B~12~ (1 g) was injected intramuscularly 1 week before day 1 of cycle 1 and again every 9 weeks until study discontinuation. A phase I dose-escalation trial of sunitinib in combination with pemetrexed conducted outside of Japan had demonstrated tolerability of the combination of sunitinib at 37.5 mg (CDD schedule) or 50 mg (Schedule 2/1) with pemetrexed at 500 mg/m^2^ \[[@CR13]\]. On the basis of these results, we selected the starting doses of sunitinib in the present study as 37.5 mg for the CDD schedule cohort and 50 mg for the Schedule 2/1 cohort. Doses were interrupted or reduced if adverse events of grade 3 or 4 were observed. Doses were delayed if a patient did not meet the following criteria on the first day of each subsequent cycle: absolute neutrophil count of ≥2,000 cells/μL, platelet count of ≥100,000 cells/μL, and calculated creatinine clearance of ≥45 mL/min. Patients were allowed to undergo a maximum of two dose reductions of either drug; the minimum dose for pemetrexed was 250 mg/m^2^ and that for sunitinib was 25 mg/day. Treatment was repeated in a 21-day (3-week) cycle until disease progression, unacceptable toxicity, or withdrawal of patient consent occurred. DLTs were assessed during the first treatment cycle and were used to determine whether the dose or schedule was feasible. They were defined as drug-related toxicities of grade 3 or 4, including neutropenia (grade 3 with infection, grade 4 for ≥7 days, or febrile for \>24 h), thrombocytopenia (grade ≥ 3 with bleeding or grade 4 for ≥7 days), lymphopenia accompanied by an opportunistic infection, or any nonhematologic toxicity of grade 3 or 4 for ≥7 days. Initially, six patients were randomized to each dosing schedule (three patients each). If no more than one of the three patients experienced a DLT by day 21 of cycle 1, then an additional six patients (three patients each) were randomized for treatment at the same dose. If ≥2/3 or ≥2/6 patients on a schedule experienced a DLT, the dose was reduced and three additional patients were enrolled.

All patients provided written informed consent. The study was approved by the institutional review board of Kinki University Hospital and was performed in accordance with the International Conference on Harmonization of Good Clinical Practice guidelines, as well as with applicable local laws and regulatory requirements.

Study assessments {#Sec5}
-----------------

Safety was assessed according to CTCAE version 3.0. In patients with measurable disease, objective response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 \[[@CR14]\].

Pharmacokinetic evaluations {#Sec6}
---------------------------

For patients randomized to the CDD schedule, blood samples were collected on day 1 of cycle 2 (sunitinib, before as well as 2, 4, 6, 8, 10, and 24 h after dosing; pemetrexed, before as well as 10 min and 1, 2, 4, 6, 8, 10, and 24 h after dosing) to evaluate pharmacokinetic parameters. For patients randomized to Schedule 2/1, blood samples were collected on day 14 of cycle 1 to determine the trough level of sunitinib. The plasma concentrations of sunitinib, its active metabolite (SU12662), and pemetrexed were measured by validated high-performance liquid chromatography and tandem mass spectrometry, with the lower limits of detection being 0.1 ng/mL for sunitinib and SU12662 and 0.1 μg/mL for pemetrexed. Standard plasma pharmacokinetic parameters were estimated by noncompartmental methods. They included the maximum plasma concentration (*C*~max~), plasma predose concentration (*C*~trough~), time to *C*~max~ (*T*~max~), area under the plasma concentration-time profile from time zero to 24 h after dosing (AUC~0--24~), area under the plasma concentration-time profile from time zero to infinity (AUC~0--∞~), elimination half-life (*t*~1/2~), oral clearance (CL/F), clearance (CL), and volume of distribution at steady state (*V*~ss~).

Statistical analysis {#Sec7}
--------------------

Given the exploratory nature of the study, all analyses were descriptive, with no formal statistical test performed on the data.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Twelve patients were enrolled in the study from August to November 2008: six patients for the CDD schedule and six for Schedule 2/1. The most common malignancy in the 12 treated patients was NSCLC (*n* = 9, 75%). All patients received at least one dose of the study treatment. Patient demographic and baseline characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Patient characteristics according to dosing scheduleCDD schedule (*n* = 6)Schedule 2/1 (*n* = 6)Median (range) age (years)55.5 (48--69)66.0 (57--69)Male/female (*n*)6/04/2ECOG performance status 0/1 (*n*)2/44/2Primary malignancy (*n*) NSCLC63 Pancreatic cancer01 Pancreatic neuroendocrine tumor01 Uterine sarcoma01Previous therapy (*n*) Surgery22 Chemotherapy66Number of prior regimens (*n*) 135 221 ≥310*CDD schedule* continuous daily dosing of sunitinib (37.5 mg) plus pemetrexed (500 mg/m^2^) once every 3 weeks, *Schedule 2/1* 2-weeks-on and 1-week-off dosing of sunitinib (50 mg) plus pemetrexed (500 mg/m^2^) once every 3 weeks, *ECOG* Eastern Cooperative Oncology Group, *NSCLC* non-small cell lung cancer

Treatment delivery {#Sec10}
------------------

A total of 66 cycles of treatment with sunitinib plus pemetrexed was completed, with a median number of cycles per patient of four for the CDD schedule and five for Schedule 2/1. All 12 patients were ultimately withdrawn from the study, the most common reason for which was disease progression (three patients on the CDD schedule and five patients on Schedule 2/1). Treatment was withdrawn because of adverse events in one patient on each schedule (hemoglobin decrease for the CDD schedule and febrile neutropenia for Schedule 2/1). Seven dose reductions each for sunitinib and pemetrexed were instituted (three for the CDD schedule and four for Schedule 2/1), mainly as a result of myelosuppression.

Safety {#Sec11}
------

All 12 patients were evaluable for safety analysis. None of the patients treated on the CDD schedule or Schedule 2/1 experienced a DLT, whereas all individuals experienced at least one adverse event during the study. The major adverse events during the entire treatment period are shown in Table [2](#Tab2){ref-type="table"}. The most common nonhematologic toxicities (any grade) across both schedules were fatigue (*n* = 11), taste alteration (*n* = 9), skin discoloration (*n* = 8), anorexia (*n* = 8), and fever (*n* = 8). Nonhematologic toxicities of grade 3 included diarrhea (*n* = 2) as well as fatigue, proteinuria, and dehydration (*n* = 1 each) on the CDD schedule, and an increase in alanine aminotransferase and hypertension (*n* = 1 each) on Schedule 2/1. No nonhematologic toxicities of grade 4 were observed for either schedule. The most common hematologic toxicity of grade 3 or 4 was a decrease in neutrophil number, with six patients (CDD schedule, *n* = 4; Schedule 2/1, *n* = 2) experiencing this adverse event at grade 3 and two patients (*n* = 1 for each schedule) at grade 4. Other hematologic toxicities of grade 3 or 4 included a decrease in leukocytes of grade 3 in four patients (CDD schedule, *n* = 3; Schedule 2/1, *n* = 1), a decrease in platelets of grade 3 in three patients (CDD schedule, *n* = 2; Schedule 2/1, *n* = 1), and a decrease in hemoglobin level of grade 3 in one patient (CDD schedule). Table 2Treatment-emergent (all-causality) adverse events (NCI CTCAE version 3.0) occurring with an incidence of ≥ 2 cases (or of special interest) in patients on either the CDD schedule or Schedule 2/1Adverse eventCDD schedule (*n* = 6)Schedule 2/1 (*n* = 6)Total (*n* = 12)GradeGradeAll grades^a^12341234Nonhematologic Fatigue3110600011 Taste alteration120060009 Skin discoloration500030008 Anorexia310031008 Fever310031008 AST increased400011006 Diarrhea102020005 Stomatitis110021005 ALT increased210010105 Hypoalbuminemia020012005 Hand--foot syndrome210020005 Vomiting200020004 Cough030010004 Rash210010004 Eyelid edema100020003 Cheilitis000030003 Nausea100011003 Nasopharyngitis100020003 Proteinuria001011003 Constipation100010002 Edema200000002 Infection000002002 Dehydration011000002 Pain-joint100010002 Headache200000002 Neuropathy000020002 Hypertension010000102 Hypothyroidism^b^000001001 TSH increased^b^010000001 Epistaxis^b^100000001 Hemorrhage^b^010000001Hematologic Platelets decreased3120301010 Leukocytes decreased0230041010 Neutrophils decreased004101219 Hemoglobin decreased021011005 Lymphopenia001000102 Febrile neutropenia^b^000000101*NCI CTCAE* National Cancer Institute Common Terminology Criteria for Adverse Events, *CDD* continuous daily dosing, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *TSH* thyroid-stimulating hormone^a^No adverse events of grade 5 occurred^b^Adverse events of special interest occurring with an incidence of \<2 on either the CDD schedule or Schedule 2/1

Adverse events considered to be serious occurred in three patients (CDD schedule, *n* = 2; Schedule 2/1, *n* = 1): one patient on the CDD schedule had dehydration (grade 2), one patient on the CDD schedule had infectious enteritis and dehydration (both of grade 3), and one patient on Schedule 2/1 had pyrexia (grade 2), pneumothorax (grade 1), pleural effusion (grade 1), and febrile neutropenia (grade 3). There were no deaths during the study.

Pharmacokinetics {#Sec12}
----------------

The mean plasma concentration-time profiles and pharmacokinetic parameters for sunitinib, its active metabolite (SU12662), total drug (sunitinib + SU12662), and pemetrexed for three patients who received the planned treatment on the CDD schedule are shown in Fig. [1](#Fig1){ref-type="fig"} and Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The mean *C*~trough~ for day 1 of cycle 2 was 45.6 ng/mL for sunitinib, 25.1 ng/mL for SU12662, and 70.6 ng/mL for total drug, and each of the corresponding mean plasma concentration-time profiles showed relatively slow absorption and elimination, consistent with previous observations \[[@CR15]\]. The pharmacokinetic parameters obtained for sunitinib (37.5 mg) on the CDD schedule with pemetrexed (500 mg/m^2^) in the present study did not appear to differ substantially from the dose-normalized parameters previously obtained for single dosing of sunitinib at 25 or 50 mg \[[@CR15], [@CR16]\]. The plasma concentration of pemetrexed during sunitinib continuous dosing declined with a fast elimination rate (mean *t*~1/2~ was 2.75 h), and the *t*~1/2~, CL, and *V*~ss~ values were similar to those previously obtained for single dosing of pemetrexed at 500 mg/m^2^ \[[@CR17]\]. For Schedule 2/1, the mean *C*~trough~ for day 14 of cycle 1 in six patients who received the planned treatment was 78.5 ng/mL for sunitinib, 38.2 ng/mL for SU12662, and 117.0 ng/mL for total drug. The plasma concentration of sunitinib observed for both schedules was considered to have achieved a steady state on the basis of previous results \[[@CR15]\]. The *C*~trough~ values of sunitinib, SU12662, and total drug observed for both the CDD schedule (sunitinib, 37.5 mg/day) and Schedule 2/1 (sunitinib, 50 mg/day) suggested that the plasma concentrations increased in a dose-dependent manner. Fig. 1Plasma concentration-time profiles for sunitinib, SU12662, total drug (sunitinib + SU12662), and pemetrexed on day 1 of cycle 2 for the CDD schedule. Data are means ± standard deviation (SD) for three patientsTable 3Pharmacokinetic parameters of sunitinib, SU12662, and total drug (sunitinib + SU12662) for the CDD scheduleParameterSunitinibSU12662Total drug*C*~trough~ (ng/mL)45.6 ± 11.7 (26)25.1 ± 5.08 (20)70.6 ± 13.9 (20)\[41.3\]\[28.0\]\[69.3\]*T*~max~ (h)4 (4--6)4 (4--4)4 (4--6)*C*~max~ (ng/mL)59.9 ± 10.9 (18)31.6 ± 5.49 (17)91.56 ± 14.2 (15)\[59.6\]\[34.7\]\[94.3\]AUC~0--24~ (ng·h/mL)1,190 ± 247 (21)675 ± 107 (16)1,866 ± 269 (14)\[1,161\]\[665\]\[1,951\]CL/F (L/h)32.4 ± 6.65 (20)NDND\[32.3\]*CDD* continuous daily dosing, *ND* no data, *SD* standard deviationData are arithmetic means ± SD (coefficient of variation, (%) \[median\], with the exception of those for *T*~max~, which are medians (range). Sampling was performed on day 1 of cycle 2Table 4Pharmacokinetic parameters of pemetrexed for the CDD scheduleParameterValue*T*~max~ (h)0.167 (0.167--0.167)*C*~max~ (μg/mL)1636 ± 30.7 (19) \[167\]AUC~0--∞~ (μg·h/mL)1916 ± 36.3 (19) \[202\]*t*~1/2~ (h)2.7546 ± 0.531 (19) \[2.558\]CL (L/h)4.976 ± 1.38 (28) \[4.30\]*V*~ss~ (L)10.46 ± 3.13 (30) \[10.9\]*CDD* continuous daily dosing, *SD* standard deviationData are arithmetic means ± SD (coefficient of variation, (%) \[median\], with the exception of those for *T*~max~, which are medians (range). Sampling was performed on day 1 of cycle 2

Tumor response {#Sec13}
--------------

Eight of the 12 patients were evaluable for response by RECIST. A partial response was observed in one patient with NSCLC on the CDD schedule, whereas five patients (two on the CDD schedule and three on Schedule 2/1) had stable disease (Fig. [2a](#Fig2){ref-type="fig"}). Most patients showed a decrease in the size of the target lesion while on the study treatment. Fig. 2Tumor response. **a** maximum percentage change in the size of the target lesion in the eight evaluable patients. *PD* progressive disease, *PR* partial response, ^†^stable disease due to a new bone lesion. **b** computed tomography of a solid tumor in the right lung of a patient indicated by ^†^ in part **a** at baseline (left panel) and on day 14 of cycle 2 for the CDD schedule. The tumor showed marked central cavitation after treatment

Discussion {#Sec14}
==========

Our feasibility study investigated the overall safety of sunitinib administered on the CDD schedule or Schedule 2/1 in combination with pemetrexed for the treatment of subjects with advanced refractory solid tumors. Phase I studies of sunitinib monotherapy have been performed according to various schedules, including a 3-week cycle consisting of treatment for 2 weeks followed by a 1-week rest period (Schedule 2/1), a 4-week cycle comprising treatment for 2 weeks followed by 2 weeks off treatment (Schedule 2/2), or a 6-week cycle of treatment for 4 weeks followed by 2 weeks off treatment (Schedule 4/2) \[[@CR18], [@CR19]\]. Daily dosing with sunitinib at 50 mg resulted in a target plasma concentration greater than the 50 ng/mL required to inhibit PDGFR and VEGFR, and DLTs of fatigue, asthenia, and thrombocytopenia occurred at a dose of 75 mg on all schedules; a recommended dose of 50 mg was thus established for Schedules 2/1, 2/2, and 4/2 \[[@CR4]\]. Preclinical and clinical studies showing tumor regrowth during the off-dosing period suggested that better tumor control might be achieved with sunitinib on a CDD schedule \[[@CR20], [@CR21]\]. Subsequent clinical trials demonstrated that CDD of sunitinib at 37.5 mg was well tolerated and showed clinical activity largely similar to that observed for administration on intermittent schedules, providing flexibility in dosing schedule \[[@CR22]--[@CR24]\].

Phase I studies have shown that myelosuppression is the predominant DLT of pemetrexed \[[@CR25]\]. We previously found that the maximum tolerated dose of pemetrexed supplemented with folic acid and vitamin B~12~ was 1,200 mg/m^2^, which was twice the previously determined such dose (600 mg/m^2^) for administration without vitamin supplementation \[[@CR17], [@CR26]\]. The results of randomized trials comparing pemetrexed at 500 mg/m^2^ versus 900 mg/m^2^ or 1,000 mg/m^2^ in patients with recurrent NSCLC showed that the higher doses did not exhibit a greater clinical efficacy than the lower dose, thereby establishing the clinically recommended dose of 500 mg/m^2^ for pemetrexed supplemented with folic acid and vitamin B~12~ \[[@CR27], [@CR28]\].

Given the differences in metabolism and elimination between sunitinib and pemetrexed, we assessed the safety of the combination of recommended doses of these drugs. We initiated treatment with sunitinib at 50 mg/day on Schedule 2/1 or at 37.5 mg on the CDD schedule together with pemetrexed at 500 mg/m^2^. There were no DLTs in the 12 patients of the present study who received both drugs at the recommended single-agent doses. Most toxicities were mild or moderate in extent, and similar in type to those observed in the monotherapy studies of sunitinib and pemetrexed. All toxicities of grade 3 or 4 were reversible and manageable with symptomatic treatment and dose reduction or interruption. Hypertension is often associated with treatment with angiogenesis inhibitors, including sunitinib, but this condition developed in only two patients in the present study and, in both cases, blood pressure was controlled with standard antihypertensive therapy. No patients experienced cardiac abnormalities, including electrocardiogram (ECG) changes or a decline in left ventricular ejection fraction to below the lower limit (50%).

In the present study, the full pharmacokinetic profile was evaluated at steady state only for the CDD schedule, given that pharmacokinetic interaction is generally assessed with high drug exposure. The concomitant administration of pemetrexed and sunitinib showed no marked effect on the pharmacokinetics of either drug, compared with previous single-dosing results. These findings suggest that there was no substantial pharmacokinetic interaction between sunitinib and pemetrexed, consistent with the differences in the pathways of metabolism and elimination for these drugs. Sunitinib is primarily metabolized by cytochrome P450-3A4 (CYP3A4) in hepatic microsomes, whereas pemetrexed is not metabolized to an appreciable extent, but is primarily eliminated renally \[[@CR4], [@CR29]\]. It is not likely that sunitinib or its metabolites inhibit the renal elimination of pemetrexed. In addition, *in vitro* studies with human liver microsomes suggested that pemetrexed administration is not likely to result in clinically relevant inhibition of the metabolic clearance of drugs metabolized by CYP3A \[[@CR30]\]. The trough plasma concentrations for total drug (sunitinib + SU12662) in both treatment arms of the present study suggest that sufficient exposure was achieved with regard to target inhibition, according to the required inhibitory concentration values.

Although tumor evaluation was not the primary objective of the present study, and the small sample size precludes any definitive conclusions regarding treatment efficacy, antitumor activity data were suggestive of a potential clinical benefit. It is possible that further pemetrexed studies might be restricted to patients with nonsquamous NSCLC because of the pemetrexed label indications \[[@CR31]\]. However, the one partial response in the present study was observed in a patient with squamous NSCLC; the tumor cavitation apparent in this patient after study treatment (Fig. [2b](#Fig2){ref-type="fig"}) is characteristic of the antitumor effect of antiangiogenic therapy. Given that sunitinib has shown promising single-agent activity in patients with recurrent NSCLC \[[@CR22], [@CR32]\], further research is warranted to determine whether sunitinib might improve the effect of pemetrexed, not only in nonsquamous NSCLC, but also in squamous NSCLC.

In conclusion, combination therapy with sunitinib administered according to Schedule 2/1 (50 mg/day), or a CDD schedule (37.5 mg/day) together with standard-dose pemetrexed (500 mg/m^2^), was well tolerated in previously treated patients with advanced solid tumors. In both dosing schedules, sunitinib exposure remained above the target plasma concentration in the presence of pemetrexed. Given that both sunitinib and pemetrexed have shown antitumor activity as single agents for various types of solid tumors including NSCLC, sunitinib in combination with pemetrexed is a viable therapeutic regimen that warrants future investigation.
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